Advertisement

Hysterectomy pp 299-305 | Cite as

Perioperative Management of Antithrombotic Therapy in the Periprocedural Period of Patients Undergoing Hysterectomy

  • Verena LimpergerEmail author
  • Florian Langer
  • Rolf Mesters
  • Ralf Ulrich Trappe
  • Ulrike Nowak-Göttl
Chapter
  • 698 Downloads

Abstract

Oral anticoagulants (Vitamin-K-Antagonists, Dabigatran, Rivaroxaban, Apixaban, Edoxaban) or antiplatelet agents (Acetylsalicylic acid, Clopidogrel, Prasugrel, Ticagrelor) are effective in preventing thromboembolic diseases. In case of interventional of surgical procedures patients with indications for chronic anticoagulation (atrial fibrillation, valve prosthesis, venous thromboembolism) or use of antiplatelet agents (cerebrovascular events, cardiovascular events) will require interruption of antithrombotic/antiplatelet therapy with the need of replacement with a short-acting agent. Due to limited data available from randomized studies and meta-analyses the evidence level is low in the majority of recommendations. Therefore for each patient the bleeding and thrombosis risk depending on the individual patient constitution and the planned intervention must be weighted. In patients with an intermediate risk for thrombosis the bleeding risk of the scheduled intervention will influence the bridging recommendation: In patients with a low bleeding risk oral anticoagulation/ antiplatelet therapy can be continued or reduced in intensity. In patients with an intermediate or high bleeding risk along with a low thrombosis risk a temporary interruption of the anticoagulation/antiplatelet therapy is feasible. In patients with a high thrombosis and bleeding risk anticoagulation should be bridged with unfractionated heparin (renal insufficiency) or low molecular weight heparin. In the latter risk situation, inhibition of platelet function can be achieved with short-lasting GPIIb-IIIa inhibitors (Eptifibatide, Tirofiban). Prior to intervention patients treated with the new oral anticoagulants (Dabigatran; Rivaroxaban; Apixaban; Edoxaban) are requested to temporary interrupt the anticoagulation depending on the individual drug half-life and their renal function. Bridging therapy with heparin prior to intervention is not necessary with the new/ direct oral anticoagulants.

Keywords

Bridging Oral anticoagulants Platelet function inhibition New oral anticoagulants Direct oral anticoagulants 

References

  1. 1.
    Angiolillo DJ, Firstenberg MS, Price MJ, et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery. A randomized controlled trial. JAMA. 2012;307:265–74.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Baglin T. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban. Br J Haematol. 2013;163:160–7.PubMedGoogle Scholar
  3. 3.
    BRIDGE study investigators. Bridging anticoagulation. Is it needed when warfarin is interrupted around the time of a surgery or procedure – cardiology patient page. Circulation. 2012;125:e496–8.CrossRefGoogle Scholar
  4. 4.
    Chan L, Pisano M. Edoxaban (savaysa): a factor xa inhibitor. P T. 2015;40:651–95.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Dimitrova G, Tulman DB, Bergese SD. Perioperative management of antiplatelet therapy in patients with drug-eluting stents. HSR Proc Intensive Care Cardiovas Anesth. 2012;4:153–67.Google Scholar
  6. 6.
    Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood. 2011;117:5044–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Douketis JD, Spyropoulos AC, Spencer FA, American College of Chest Surgeons, et al. Perioperative management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [erratum appears in Chest 2012;141(4):1129]. Chest. 2012;141(Suppl 2):e326S–50S.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hammerstingl C, Schmitz A, Fimmers R, Omran H. Bridging of chronic oral anticoagulation with enoxaparin in patients with atrial fibrillation: results from the prospective BRAVE registry. Cardiovasc Ther. 2009;27:230–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Halbritter KM, Wawer A, Beyer J, Oettler W, Schellong SM. Bridging anticoagulation for patients on long-term vitamin-K-antagonists. A prospective registry of 311 episodes. J Thromb Haemost. 2005;3:2823–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Healey J, Eiklboom J, Douketis J, et al. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin – results from the randomised evaluation of long-term anticoagulation therapy (RE-LY) randomised trial. Circulation. 2012;126:343–8.Google Scholar
  11. 11.
    Hillarp A, Baghaei F, Fagerberg BI, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9:133–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Lip GY, Huber K, Andreotti F, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103:13–28.CrossRefPubMedGoogle Scholar
  13. 13.
    Joist JH, George JN. Hemostatic abnormalities in liver and renal disease. In: RW C, Hirsh J, VJ M, et al., editors. Hemostasis and thrombosis. Basic principals and clinical practice. Philadelphia: Lippincott, Williams & Wilkins; 2004. p. 955–73.Google Scholar
  14. 14.
    Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506–11.CrossRefPubMedGoogle Scholar
  15. 15.
    Koscielny J, Beyer-Westendorf J, von Heymann C, et al. Risk of bleeding and haemorrhagic complication with rivaroxaban-periprocedural management of haemostasis – Konsensus. Hamostaseologie. 2012;32(4):287–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Koscielny J, Rutkauskaite E. Preinterventional change in the clotting medication. Viszeralmedizin (Gastrointestinal Medicine and Surgery). 2013;29:1–13.Google Scholar
  17. 17.
    Korte W, Cattaneo M, PG C, et al. Perioperative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (ÖGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost. 2011;105(5):743–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Kozek-Langenecker S, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol. 2013;30:270–382.CrossRefPubMedGoogle Scholar
  19. 19.
    Lijfering WM, J.-L B, Veeger N, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113(21):5314–22.CrossRefPubMedGoogle Scholar
  20. 20.
    Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood. 1997;90:2515–21.PubMedGoogle Scholar
  21. 21.
    Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Hematology. 2012;529-535Google Scholar
  22. 22.
    Levi M, Eerenberg E, Kamphuisen PW. Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents. J Thromb Haemost. 2011;9:1705–12.CrossRefPubMedGoogle Scholar
  23. 23.
    Levy JH, Faraoni D, Spring JL, Douketis JD, Samama CM. Managing new oral anticoagulants in the perioperative and intensive care unit setting. Anesthesiology. 2013;118:1466–74.CrossRefPubMedGoogle Scholar
  24. 24.
    Patel M, Mahaffey K, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Patel JP, Arya R. The current status of bridging anticoagulation. Br J Haematol. 2013; doi: 10.1111/bjh.12644.Google Scholar
  26. 26.
    Pfanner G, Koscielny J, Pernerstorfer T, et al. Die präoperative Blutungsanamnese. Empfehlungen der Arbeitsgruppe perioperative Gerinnung (AGPG) der Österreichischen Gesellschaft für Anästhesiologie, Reanimation und Intensivmedizin (ÖGARI). Anaesthesist. 2007;56(6):604–11. [in German]CrossRefPubMedGoogle Scholar
  27. 27.
    Rodeghiero F, Tosetto A, Abshire T, Arnold DM, Coller B, James P, Neunert C, Lillicrap D. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost. 2010;8:2063–5. on behalf of the ISTH/SSC Joint VWF and Perinatal/ Pediatric Haemostasis Subcommittees Working Group: http://www.wfh.org/en/resources/bleeding-assessment-tool-isth-batt CrossRefPubMedGoogle Scholar
  28. 28.
    Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379–87.CrossRefPubMedGoogle Scholar
  29. 29.
    Savonitto S, D’Urbano M, Caracciolo M, et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth. 2010;104:285–91.Google Scholar
  30. 30.
    Schulman S, Kearon C, on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost. 2005;3:692–4.CrossRefPubMedGoogle Scholar
  31. 31.
    Schellong SM, Haas S. Perioperative Thromboseprophylaxe – Neue orale Antikoagulanzien und ihre Anwendung. Anästhesiol Intensivmed Notfallmed Schmerzther. 2012;47:266–72. [in German]CrossRefPubMedGoogle Scholar
  32. 32.
    S3 – Leitlinie Polytrauma/Schwerverletzten-Behandlung. Deutsche Gesellschaft für Unfallchirurgie. AWMF (Arbeitskreis wissenschaftlicher medizinischer Fachgesellschaften) – Register Nr. 012/019: 1–445. [in German].Google Scholar
  33. 33.
    S3 – Leitlinie Prophylaxe der venösen Thromboembolie (VTE). AWMF (Arbeitskreis wissenschaftlicher medizinischer Fachgesellschaften) – Register Nr. 003/001: 1–243. [in German].Google Scholar
  34. 34.
    Siegal D, Yudin J, Kaatz S, Douketis J, Lim W, Spyropoulos AC. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation. 2012;126:1630–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009;374(9706):1967–74.CrossRefPubMedGoogle Scholar
  36. 36.
    Spyropoulos AC, Albaladejo P, Godier A, et al. Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. J Thromb Haemost. 2013 Aug;11(8):1593–156.CrossRefPubMedGoogle Scholar
  37. 37.
    Spyropoulos A, Douketis JD, Gerotziafas G, Kaatz S, Ortel TL, Schulman S, on behalf of the subcommittee on control of anticoagulation of the SSC of the ISTH. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy. J Thromb Haemost. 2012;10:692–4.CrossRefPubMedGoogle Scholar
  38. 38.
    The Society of Thoracic Surgeons Blood Conservation Guideline Task Force, The Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(Suppl):S27–86.Google Scholar
  39. 39.
    Thiele T, Sumnig A, Hron G, et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost. 2012;10:968–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Ufer M. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;4412:1227–46.CrossRefGoogle Scholar
  41. 41.
    van Ryn J, Tangier J, Haertter S, et al. Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.CrossRefPubMedGoogle Scholar
  42. 42.
    Vincentelli A, Susen S, le Turneau E, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2003;349:343–49.Google Scholar
  43. 43.
    Vossen CY, Conard J, Fontcuberta J, et al. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost. 2004;2:1526–32.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2018

Authors and Affiliations

  • Verena Limperger
    • 1
    Email author
  • Florian Langer
    • 2
  • Rolf Mesters
    • 3
  • Ralf Ulrich Trappe
    • 4
  • Ulrike Nowak-Göttl
    • 5
  1. 1.Institute of Clinical Chemistry, University Hospital Schleswig HolsteinKielGermany
  2. 2.II. Medizinische Klinik und PoliklinikUniversitätskliniken EppendorfHamburgGermany
  3. 3.Medizinische Klinik und Poliklinik AUniversity Hospital MünsterMünsterGermany
  4. 4.Hematology and OncologyEv. Diakonie-Krankenhaus gemeinnützige GmbHBremenGermany
  5. 5.University Hospital Schleswig-Holstein, Institute of Clinical Chemistry, Thrombosis and Haemostatsis Treatment UnitKielGermany

Personalised recommendations